Yehezkel Ben-Ari
Directeur/Membre du Conseil chez Institut National de la Santé & de la Recherche Médicale
Profil
Yehezkel Ben-Ari is the founder of Neurokin SA, which was founded in 2003.
He held the title of Director from 2003 to 2014.
Currently, he is the Director at Institut National de la Santé & de la Recherche Médicale.
Postes actifs de Yehezkel Ben-Ari
| Sociétés | Poste | Début |
|---|---|---|
Institut National de la Santé & de la Recherche Médicale
 Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Directeur/Membre du Conseil | 20/11/2009 |
Anciens postes connus de Yehezkel Ben-Ari
| Sociétés | Poste | Fin |
|---|---|---|
Neurokin SA
 Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Fondateur | 11/03/2014 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Health Technology |
Institut National de la Santé & de la Recherche Médicale
Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Commercial Services |
